Snell & Wilmer Advises New Enterprise Associates and SR One in $80 Million Series B Financing for CHARM Therapeutics

PALO ALTO – Snell & Wilmer represented clients New Enterprise Associates (NEA) and SR One in co-leading the $80 million Series B financing round for CHARM Therapeutics, Inc. (“CHARM”), a London-based biotechnology company developing next-generation menin inhibitors for the treatment of acute myeloid leukemia (AML).

The funding round will support CHARM’s efforts to advance its next-generation menin inhibitor into clinical development. The financing was co-led by NEA and SR One with participation from existing investors OrbiMed, F-Prime, NVIDIA, and Khosla Ventures.

“Securing funding from such a high-quality investor syndicate is a strong validation of our approach to overcoming menin inhibitor resistance,” said Gary D. Glick, Ph.D., Executive Chair, CHARM Therapeutics in a recent press release. “Current menin inhibitors show promise in AML treatment but are fundamentally limited by the rapid emergence of resistance mutations that cause treatment failure. Our next-generation inhibitors, discovered using our proprietary DragonFold AI platform, are specifically designed to overcome these resistance mutations and deliver the durable responses that patients need. This program represents a significant opportunity to transform outcomes for patients, and we look forward to initiating clinical development early next year.”

The Snell & Wilmer team advising NEA and SR One was led by Daniel McEvers Mahoney, P.C. and Bardia Moayedi with support from Greg Gautam, Jason Gersting, Sarah Hibbard, Amberlee Lapointe, Emily K. McCorry, and paralegal Scott Drake.

Snell & Wilmer’s corporate and securities attorneys have served as counsel to a substantial number of clients ranging from Fortune 100 companies to smaller emerging businesses. Our attorneys have provided sophisticated legal representation to biotech companies, health care and financial institutions, public utilities, homebuilders, transportation companies, restaurant and hospitality providers, athletic complexes, fitness facilities and many other types of businesses. Snell & Wilmer’s venture capital and private equity practice covers multiple aspects of the transactional arena involving public and private companies, including the structuring and execution of majority buyouts and minority investments, acquisitions (including buy- and sell-side deals, as well as negotiated and auction deals), financings (including 144A transactions and PIPEs), going-private transactions, and spin-off transactions. Our venture capital and private equity attorneys advise both domestic and international funds, including venture capital, private equity, hedge, mezzanine, real estate opportunity, fund-of-funds, exchange, and other private investment funds.